Validations Queue
111,300 candidate doc → node links pending adjudication. Each was auto-generated by cosine similarity ≥ 0.55 between document and prediction embeddings (bge-base-en-v1.5, 768-dim). Showing page 33 of 88, 50 rows by similarity. Adjudicating updates doc_node_links.reviewed=true with the chosen polarity, writes per-link rows to audit_log, and removes the row from this queue. Phase 4 inference will use confirmed corroborates/contradicts links as Bayesian evidence.
Pending (total)
111,300
Reviewed
13
Filtered
4,390
page 33 / 88
Showing on page
50
Filters
URL params control source + min-similarity threshold
Bulk auto-confirm by similarity threshold
Confirm or label (corroborates / contradicts) all unreviewed links above a similarity threshold in one transaction. Each affected row writes a per-link audit_log entry. Capped at 1,000 links per call. Use Preview first.
Source0 selected · 0 visible
Bulk action
| Sim | Doc | Source | Pred | Domain | Prior | |
|---|---|---|---|---|---|---|
| 0.59 | FDA ANDA040779: ACETAMINOPHEN AND CODEINE PHOSPHATE (ACETAMINOPHEN) — AMNEAL PHARMS NY | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040778: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS NY | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA210655: PERSERIS KIT (RISPERIDONE) — INDIVIOR | fda 2026-04-30 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA211489: DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE (DAPAGLIFLOZIN, METFORMIN HYDROCHLORIDE) — AUROBINDO PHARMA | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA219013: ATROPINE SULFATE (ATROPINE SULFATE) — EDENBRIDGE PHARMS | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA211545: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALKEM LABS LTD | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA216718: SKYCLARYS (OMAVELOXOLONE) — BIOGEN US | fda 2026-04-07 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA211560: DAPAGLIFLOZIN (DAPAGLIFLOZIN) — ALEMBIC | fda 2026-04-06 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA075388: BUSPIRONE HYDROCHLORIDE (BUSPIRONE HYDROCHLORIDE) — OXFORD PHARMS | fda 2026-04-15 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA218840: CALCIUM GLUCONATE (CALCIUM GLUCONATE) — CAPLIN | fda 2026-05-04 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA NDA019726: ZOLADEX (GOSERELIN ACETATE) — TERSERA | fda 2026-05-06 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA203103: PROPRANOLOL HYDROCHLORIDE (PROPRANOLOL HYDROCHLORIDE) — IPCA LABS LTD | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761170: PHESGO (PERTUZUMAB, TRASTUZUMAB, AND HYALURONIDASE-ZZXF) — GENENTECH INC | fda 2026-05-18 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA207947: UPTRAVI (SELEXIPAG) — ACTELION | fda 2026-05-23 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA211020: BUPROPION HYDROCHLORIDE (BUPROPION HYDROCHLORIDE) — GRAVITI PHARMS | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208175: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (PHENTERMINE HYDROCHLORIDE) — DR REDDYS LABS SA | fda 2026-05-29 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA218096: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — APOTEX | fda 2026-06-03 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA BLA761063: EMGALITY (GALCANEZUMAB-GNLM) — ELI LILLY AND CO | fda 2026-06-05 | 235_031 Eli Lilly perilously close to $1 trillion market cap at ~$950B. Alex Wissner-Gross | Markets/Stocks | 39% | |
| 0.59 | FDA ANDA219370: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — AUSON | fda 2026-06-09 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA218821: TOFACITINIB CITRATE (TOFACITINIB CITRATE) — CONCORD BIOTECH LTD | fda 2026-06-09 | TK13 Biotech/Synbio Safety Event | — | 15% | |
| 0.59 | FDA ANDA201972: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AUROLIFE PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA203447: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ANI PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040331: MEPERIDINE HYDROCHLORIDE (MEPERIDINE HYDROCHLORIDE) — EPIC PHARMA LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA201278: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — RHODES PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA077723: HYDROCODONE BITARTRATE AND IBUPROFEN (HYDROCODONE BITARTRATE) — STRIDES PHARMA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA218754: APREPITANT (APREPITANT) — AZURITY | fda 2026-06-16 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA202677: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — ALVOGEN | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA076636: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — ACTAVIS ELIZABETH | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA019892: DILAUDID (HYDROMORPHONE HYDROCHLORIDE) — RHODES PHARMS | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA087463: OXYCET (ACETAMINOPHEN) — SPECGX LLC | fda 2026-06-18 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA213414: DAPSONE (DAPSONE) — ALEMBIC | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA020622: COPAXONE (GLATIRAMER ACETATE) — TEVA PHARMS USA | fda 2026-06-22 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA202160: OXYCODONE HYDROCHLORIDE (OXYCODONE HYDROCHLORIDE) — AUROLIFE PHARMA LLC | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA217737: IOHEXOL (IOHEXOL) — AMNEAL | fda 2026-06-25 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA075982: TRAMADOL HYDROCHLORIDE (TRAMADOL HYDROCHLORIDE) — PLIVA | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA040777: OXYCODONE AND ACETAMINOPHEN (ACETAMINOPHEN) — AMNEAL PHARMS | fda 2026-06-18 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA NDA021150: ZYRTEC-D 12 HOUR (CETIRIZINE HYDROCHLORIDE) — KENVUE BRANDS | fda 2026-07-02 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA208539: TICAGRELOR (TICAGRELOR) — MICRO LABS | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA079099: LAMOTRIGINE (LAMOTRIGINE) — GLENMARK PHARMS LTD | fda 2026-04-17 | 233_019 Alpha plans to conduct a million-student pharmaceutical-grade randomized control trial on Timeback. Joe Liemandt | Education | 35% | |
| 0.59 | FDA ANDA091427: PAROXETINE HYDROCHLORIDE (PAROXETINE HYDROCHLORIDE) — AUROBINDO PHARMA USA | fda 2026-04-06 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA079162: TOPIRAMATE (TOPIRAMATE) — INVAGEN PHARMS | fda 2026-04-24 | COD_BIO_002 An AI-designed Isomorphic or peer drug enters or completes Phase 1 by end 2027 Codex Research Pack | Biotech/Longevity | 50% | |
| 0.59 | FDA ANDA078257: ONDANSETRON HYDROCHLORIDE (ONDANSETRON HYDROCHLORIDE) — ONESOURCE SPECIALTY | fda 2026-04-15 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA BLA761235: VABYSMO (FARICIMAB-SVOA) — GENENTECH INC | fda 2026-04-09 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA NDA021880: REVLIMID (LENALIDOMIDE) — BRISTOL MYERS SQUIBB | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA220493: BUPIVACAINE HYDROCHLORIDE (BUPIVACAINE HYDROCHLORIDE) — ANTHEA PHARMA | fda 2026-04-22 | COD_BIO_001 FDA finalizes or materially advances AI-for-drug-submission guidance by end 2026 Codex Research Pack | Biotech/Longevity | 47% | |
| 0.59 | FDA ANDA210480: LENALIDOMIDE (LENALIDOMIDE) — ALVOGEN | fda 2026-04-27 | CMQ_026 NVIDIA silicon roadmap: Blackwell (2025) → Vera Rubin (2026) → Vera Rubin Ultra (2027) → Feynman (2028) — annual architectural cadence. Jensen Huang | Semis | 83% | |
| 0.59 | FDA ANDA091655: ESCITALOPRAM OXALATE (ESCITALOPRAM OXALATE) — MICRO LABS | fda 2026-04-22 | IND_010 Autonomous orbital manufacturing (facilitated by companies like Varda Space Industries) will successfully return pharmaceutical products processed in microgravity that are commercially superior to those manufactured on Earth by 2026 — new Biotech front... Jared Isaacman | Biotech/Longevity | 43% | |
| 0.59 | FDA ANDA216992: DEFLAZACORT (DEFLAZACORT) — UPSHER SMITH LABS | fda 2026-04-09 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA220328: FLUVOXAMINE MALEATE (FLUVOXAMINE MALEATE) — APPCO | fda 2026-04-30 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% | |
| 0.59 | FDA ANDA204982: PHENTERMINE HYDROCHLORIDE AND TOPIRAMATE (PHENTERMINE HYDROCHLORIDE) — ACTAVIS LABS FL INC | fda 2026-05-01 | 242_048 FDA will move to zero clinical trial model given enough Bayesian/computational evidence Alex Wissner-Gross | Biotech/Longevity | 31% |